A Biocompatible Reconstituted High-Density Lipoprotein Nano-System as a Probe for Lung Cancer Detection

Lu, Hongxiu; Zhang, Honggang; Zhang, Dong; Lu, Hongwang; Ma, Dedong

doi:10.12659/msm.895255

Cited by 19 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its ability to target specific cell types, HDL particles have been used extensively in drug delivery. Reconstituted HDL nanoparticles containing fluorescent calcium carbonate were able to serve as a probe for lung cancer detection in vivo . Their targeting mechanism relied on targeting scavenger receptor class B member I (SR‐BI), which is highly expressed on some cancerous cells and has an affinity to HDL .…”

Section: Proteinsmentioning

confidence: 99%

“…Reconstituted HDL nanoparticles containing fluorescent calcium carbonate were able to serve as a probe for lung cancer detection in vivo . Their targeting mechanism relied on targeting scavenger receptor class B member I (SR‐BI), which is highly expressed on some cancerous cells and has an affinity to HDL . In another example, lymphoma cells that express SR‐BI were also targeted effectively in vivo with synthetic, gold‐templated HDL nanoparticles .…”

Section: Proteinsmentioning

confidence: 99%

“…142 Their targeting mechanism relied on targeting scavenger receptor class B member I (SR-BI), which is highly expressed on some cancerous cells and has an affinity to HDL. 142 In another example, lymphoma cells that express SR-BI were also targeted effectively in vivo with synthetic, gold-templated HDL nanoparticles. 143 Given that the main role of HDL is lipid transport, it also plays a pivotal role in atherosclerosis.…”

Section: Lipoproteinsmentioning

confidence: 99%

See 2 more Smart Citations

Biomimetic strategies for targeted nanoparticle delivery

Dehaini

Fang

Zhang

2016

Bioengineering & Transla Med

133

View full text Add to dashboard Cite

Nanoparticle‐based drug delivery and imaging platforms have become increasingly popular over the past several decades. Among different design parameters that can affect their performance, the incorporation of targeting functionality onto nanoparticle surfaces has been a widely studied subject. Targeted formulations have the ability to improve efficacy and function by positively modulating tissue localization. Many methods exist for creating targeted nanoformulations, including the use of custom biomolecules such as antibodies or aptamers. More recently, a great amount of focus has been placed on biomimetic targeting strategies that leverage targeting interactions found directly in nature. Such strategies, which have been painstakingly selected over time by the process of evolution to maximize functionality, oftentimes enable scientists to forgo the specialized discovery processes associated with many traditional ligands and help to accelerate development of novel nanoparticle formulations. In this review, we categorize and discuss in‐depth recent works in this growing field of bioinspired research.

show abstract

Section: Proteinsmentioning

confidence: 99%

Section: Proteinsmentioning

confidence: 99%

Section: Lipoproteinsmentioning

confidence: 99%

See 1 more Smart Citation

Biomimetic strategies for targeted nanoparticle delivery

Dehaini

Fang

Zhang

2016

Bioengineering & Transla Med

133

View full text Add to dashboard Cite

show abstract

“…Animal experiments found that in the SR-BI knockout mouse model, the tumor area as well as in vitro cell proliferation and migration decreased. Lu et al [11] constructed recombinant HDL (rHDL)/MB/CCPs on the basis of rHDL to develop a safe tumor-targeting probe for tumor detection. SR-BI is highly expressed in multiple tumor cell lines, including prostate, breast, liver, rectal, pancreatic, ovarian, and nasopharyngeal cells.…”

Section: Sr-bi and Malignant Tumorsmentioning

confidence: 99%

Role of SR-BI in atherosclerosis, malignancies, and infectious diseases

An¹

2018

Infection International

View full text Add to dashboard Cite

Scavenger receptor class B type I (SR-BI) is a high-affinity receptor for high-density lipoprotein (HDL). The primary role of this receptor is the selective uptake of HDLs in the liver through reverse cholesterol transport. SR-BI interacts with HDL to regulate lipid metabolism and affects various vascular cell functions involved in atherosclerosis (As). In addition, SR-BI is involved in the development of malignant tumors and infectious diseases. This article reviews the function and potential therapeutic targets of SR-BI in As, malignancies, and infectious diseases.Keywords: Scavenger receptor class B, type I; High-density lipoprotein; Atherosclerosis; Malignant neoplasms Scavenger receptor class B type I (SR-BI) is the first natural membrane receptor for high-density lipoprotein (HDL) at the molecular level. This high-affinity receptor exhibits physiological correlation with HDL. SR-BI is mainly expressed in liver, adrenal, ovarian, and testicular tissues and is also distributed in vascular endothelial cells, smooth muscle cells, macrophages, and adrenal cortical cells. SR-BI is located in the pits on the cell surface and regulates cholesterol in the cell membrane. This protein, with a molecular weight of approximately 82 kDa, contains 509 amino acids. SR-BI contains two short intracellular N-and C-terminal cytoplasmic domains, two transmembrane domains, and one large extracellular domain, which consists of 5 to 6 cysteine residues and multiple N-linked glycosylation sites [1,2]. The extracellular loop of SR-BI can interact with many proteins, especially HDL. The predicted sequences of the SR-BI protein in various mammalian species share 70%-80% sequence homology. The classical role of SR-BI is mediating the selective uptake of HDL-cholesterol esters (CE) in vivo and in vitro by reverse cholesterol transport (RCT) [3]. SR-BI also mediates the two-way flow of unesterified cholesterol and phospholipids between lipoproteins and cells [4]. In the liver, it regulates HDL particle size and composition [5]. Numerous studies have shown that SR-BI plays a crucial role in the prevention of atherosclerosis (As). SR-BI is associated with the development of malignancies and infectious diseases. This article summarizes the role of SR-BI and its potential therapeutic targets in As, malignancies, and infectious diseases.

show abstract

“…Petri and Kratzer revealed that apoA-I could bind with SR-BI specifically expressed on brain microvascular endothelial cells and astrocytes, which contributes to transferring HDL into brain to mediate intracerebral lipid metabolism in the form of transcellular transport of endothelial cells and uptake of astrocytes (Kratzer et al, 2007;Petri et al, 2007). Besides, it has also been reported that the liposomes decorated with apoA-I could be uptaken by rat glioma cells (C6 cells) via SR-BI which is also abundant on the surface of cancer cells (Hong et al, 2007;Park et al, 2010;Lu et al, 2015;Rajora and Zheng, 2016). Relating to or produced by the mediated effect of apoA-I as above, rHDL might be endowed with the excellent capacity of transporting across BBB, accumulating in the brain and tumor.…”

Section: Introductionmentioning

confidence: 99%

Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells

Han

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Reconstituted high density lipoprotein (rHDL) has been regarded as a promising brain-targeting vehicle for anti-glioma drugs under the mediation of apolipoprotein A-I (apoA-I). However, some stability issues relating to drug leakage and consequent reduced targeting efficiency in the course of discoidal rHDL (d-rHDL) circulating in blood hinder its broad application. The objective of the study was to develop a novel stabilized d-rHDL by replacing cholesterol and apoA-I with mono-cholesterol glutarate (MCG) modified apoA-I (termed as mA) and to evaluate its allosteric behavior and glioma targeting. MCG was synthesized through esterifying the hydroxyl of cholesterol with glutaric anhydride and characterized by FI-IR and 1 H NMR. d-rHDL assembled with mA (termed as m-d-rHDL) presented similar properties such as minute particle size and disk-like appearance resembling nascent HDL. Morphological transformation observation and in vitro release plots convinced that the modification of cholesterol could effectively inhibit the remolding of d-rHDL. The uptake of m-d-rHDL by LCAT-pretreated bEND.3 cells was significantly higher than that of d-rHDL, thereby serving as another proof for the capability of m-d-rHDL in enhancing targeting property. Besides, apoA-I anchoring into m-d-rHDL played a critical role in the endocytosis process into bEND.3 cells and C6 cells, which implied the possibility of traversing blood brain barrier and accumulating in the brain and glioma. These results suggested that the modification toward cholesterol to improve the stability of d-rHDL is advantageous, and that this obtained m-d-rHDL revealed great potential for realization of suppressing the remolding of d-rHDL in the brain-targeted treatment of glioma for drug delivery.

show abstract

A Biocompatible Reconstituted High-Density Lipoprotein Nano-System as a Probe for Lung Cancer Detection

Cited by 19 publications

References 14 publications

Biomimetic strategies for targeted nanoparticle delivery

Biomimetic strategies for targeted nanoparticle delivery

Role of SR-BI in atherosclerosis, malignancies, and infectious diseases

Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells

Contact Info

Product

Resources

About